Monday, October 26, 2026 · Daily editionET --:--:--

Finished

ADAI - Home Care in Intelligent Environments Clinical Care Ecosystem for the Management of Home Digital Therapies Through the Use of Assistive Robots and Clinical Predictive Systems Based on Artificial Intelligence Systems

NCT07566728 · IRCCS Centro Neurolesi Bonino Pulejo · Updated 5 May 2026

What is being tested
CLINICAL INVESTIGATION WITH A MEDICAL DEVICE MARKED CE
For
Neurodegenerative Disease; Artificial Intelligence (AI); Mild Cognitive Impairment (MCI)
Kind of study
Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
Who can join
Ages 40 years to 80 years. About 23 people. The full rules are on the registry page.
Where
Italy
When
Starts or started 22 Sept 2025, ends 31 Oct 2025. Registered 5 May 2026.
Results
None posted yet.

In the researchers' words

Dementia is a neurocognitive disorder that causes a deterioration in cognitive function, significantly impacting social and work abilities and daily activities. Alzheimer's disease is diagnosed when cognitive decline affects at least two cognitive domains, one of which must involve memory. Mild Cognitive Impairment (MCI) is a critical diagnosis as it represents a potentially early stage of cognitive decline. In the DSM-5, MCI is defined as a "minor neurocognitive disorder," characterized by functional decline affecting at least one of six cognitive domains: memory and learning, language, visuospatial function, attention, executive function, and social functioning. It is important to emphasize that this decline is not severe enough to significantly impair the patient's daily activities. In this context, support for people with MCI and dementia is crucial, not only at the family and social level, but also through the adoption of innovative technological solutions. Artificial intelligence (AI) is emerging as a valuable tool for early diagnosis, and through machine learning processes, it is possible to predict cognitive decline, thus providing personalized treatment and day-to-day patient management. This allows for intervention at a less advanced stage of the disease, thus slowing its progression, while maintaining autonomy and independence for as long as possible, which tends to…
ClinicalTrials.gov, NCT07566728

Sites

  • IRCCS Centro Neurolesi Bonino PulejoMessina, Messina, Italy